Literature DB >> 28300430

Calculated Daily Insulin Dosages Overestimate Prescribed Insulin Doses in Type 2 Diabetes: A Primary Care Database Study.

Karel Kostev1, Wolfgang Rathmann2.   

Abstract

BACKGROUND: The aim was to compare the prescribed and calculated daily insulin dosages based on prescription data in type 2 diabetes patients in a general practice database.
METHODS: A total of 17 782 type 2 diabetes patients (age: 70.0 ± 11.5 years; 52% males; 16% diabetologist care) with ≥2 insulin prescriptions from 834 practices were analyzed (Disease Analyser: 01/2011-12/2015). Prescribed daily dosage (PDD) (physician documentation) and calculated daily dose (CDD) (pack size × strength × volume / days between 2 prescriptions) were calculated for short-acting, long-acting, and premixed insulins. PDD and CDD were compared using paired t-tests. Linear regression models assessed the associations of insulin dosage difference (CDD-PDD) with age, sex, diabetologist care, private health insurance, obesity, HbA1c, hypertension, hyperlipidemia, macro- and microvascular complications.
RESULTS: Mean [SD] CDDs were higher than PDDs for short-acting (52 [28] vs 48 [26] units/day), long-acting (30 [20] vs 24 [15] units/day), and premixed (46 [26] vs 40 [21] units/day) insulins (all P < .05). In regression models, age (per year) was associated with higher CDD-PDD differences (+0.11, +0.04, +0.10; P < .01) for short-, long-acting, and premixed insulins, respectively. Diabetologist care was related to lower differences (-2.92, -1.02, -3.65; all P < .05). HbA1c was associated with higher differences in long-acting and premixed insulins, but was related to a lower difference in short-acting insulins (all P < .05).
CONCLUSIONS: CDD in primary care database studies substantially overestimate the PDD (8-25%). Age, diabetologist care, and glycemic control were related to CDD-PDD differences. Priming and safety shots with pens, dosing errors, or the accumulation of insulin reserves by patients may be underlying reasons.

Entities:  

Keywords:  adherence; daily dose; diabetes; insulin; primary care

Mesh:

Substances:

Year:  2016        PMID: 28300430      PMCID: PMC5505420          DOI: 10.1177/1932296816676187

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  12 in total

1.  Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.

Authors:  S E Holden; S Jenkins-Jones; C Ll Morgan; G Schernthaner; C J Currie
Journal:  Diabetes Obes Metab       Date:  2014-12-10       Impact factor: 6.577

2.  The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin?

Authors:  Joyce A Cramer; Mary Jo Pugh
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

3.  High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events.

Authors:  R M Stoekenbroek; K L Rensing; S J Bernelot Moens; M Nieuwdorp; J H DeVries; A H Zwinderman; E S Stroes; C J Currie; B A Hutten
Journal:  Atherosclerosis       Date:  2015-03-30       Impact factor: 5.162

4.  Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.

Authors:  W Rathmann; B Bongaerts; K Kostev
Journal:  Diabetes Obes Metab       Date:  2016-05-16       Impact factor: 6.577

5.  Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010).

Authors:  Karel Kostev; Wolfgang Rathmann
Journal:  Prim Care Diabetes       Date:  2013-04-20       Impact factor: 2.459

6.  Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies.

Authors:  H Becher; K Kostev; D Schröder-Bernhardi
Journal:  Int J Clin Pharmacol Ther       Date:  2009-10       Impact factor: 1.366

Review 7.  Insulin therapy for type 2 diabetes mellitus.

Authors:  Amisha Wallia; Mark E Molitch
Journal:  JAMA       Date:  2014-06-11       Impact factor: 56.272

8.  Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.

Authors:  Elias S Siraj; Daniel J Rubin; Matthew C Riddle; Michael E Miller; Fang-Chi Hsu; Faramarz Ismail-Beigi; Shyh-Huei Chen; Walter T Ambrosius; Abraham Thomas; William Bestermann; John B Buse; Saul Genuth; Carol Joyce; Christopher S Kovacs; Patrick J O'Connor; Ronald J Sigal; Sol Solomon
Journal:  Diabetes Care       Date:  2015-10-13       Impact factor: 19.112

9.  Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2016-07-12

10.  Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.

Authors:  K Khunti; A Nikolajsen; B L Thorsted; M Andersen; M J Davies; S K Paul
Journal:  Diabetes Obes Metab       Date:  2016-02-09       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.